Table 3.

Compare hs-miR-210-3p between psoriasis (PSO), psoriatic arthritis (PSA), and PSA post-anti-TNFα biologics agent treatment

ANOVA	Multiple comparisons	Bonferroni
hsa-miR-210-3p	Sum of squares	df	Mean square	Sig.
Between groups	2.181	2	1.090	.022*
Within groups	.844	6	.141
Total	3.024	8
Compared between 3 groups (N = 9)		Std. error	Sig.	95% Confidence interval
				Lower bound	Upper bound
PSO (n = 3)	PSA-NO biologics	0.306	0.044*	0.034	2.047
	PSA-POST biologics	0.306	1.000	− 1.014	0.998
PSA-NO biologics (n = 3)	PSO	0.306	0.044*	− 2.047	− 0.034
	PSA-POST biologics	0.306	0.042*	− 2.055	− 0.042
PSA-POST biologics (n = 3)	PSO	0.306	1.000	− 0.998	1.014
	PSA-NO biologics	0.306	0.042*	0.042	2.055

Biologics indicate anti-TNF-alpha therapy

CI confidence interval, Std. standard, PSA psoriatic arthritis, PSO psoriasis, hsa Homo sapiens, miR microRNA

*p < 0.05